Clinical trials: Coronary Stenting
Cardiovascular Diseases
A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry)
The objective of this post marketing observational registry is to evaluate clinical outcomes (safety and performance) in an all-comers population with coronary artery disease (CAD) treated with the Polymer Free Sirolimus Eluting…
- Trial name
- NCT06412250
- Where
- 32 sites in India, Italy and 2 more
- Volunteers
- 2,000 people
- Sponsor
- Translumina Therapeutics Pvt Ltd.
Coronary Artery Disease
Clinical Study Comparing Single Long BioMimeTM Morph Coronary Stent System vs. Two Overlapping Xience Family Coronary Stent Systems in the Treatment of Patients With Long de Novo Lesions.
A prospective, active control, open-label, multinational, randomized clinical trial comparing single long BioMime™ Morph Coronary Stent System vs.
- Trial name
- Morph RCT-1 (NCT03721614)
- Testing
- BioMime™ Morph - Sirolimus Eluting Coronary Stent System, Xience family Everolimus Coronary Stent Systems
- Volunteers
- 200 people
- Sponsor
- Meril Life Sciences Pvt. Ltd.
Coronary Artery Disease
Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions
The purpose of the this trial is to evaluate the clinical safety and efficacy of Cilostazol eluting stent system (CES-1) for the treatment of single de novo lesions in native coronary arteries.
- Trial name
- NCT03189641
- Testing
- Cilostazol eluting stent system (CES-1)
- Where
- 6 sites in Japan
- Volunteers
- 30 people
- Sponsor
- JIMRO Co., Ltd.
Treatment of Symptomatic Ischemic Heart Disease
The European Cobalt STent With Antiproliferative for Restenosis Trial (EuroSTAR Trial)
Two consecutive cohorts of subjects were each treated with the CoStar stent loaded with a different paclitaxel dose regimen. The first 145 subjects (Arm I), enrolled between 20 January 2004 and 26 May 2004, were treated with 10…
- Trial name
- NCT00974181
- Testing
- Conor Medsystems COSTAR™ stent (10 µg Paclitaxel), Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)
- Where
- Italy
- Volunteers
- 282 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
PROMUS Element Plus US Post-Approval Study
This study is designed to observe clinical outcomes in patients receiving the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice.
- Trial name
- NCT01589978
- Testing
- PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
- Where
- 52 sites in United States
- Volunteers
- 2,681 people
- Sponsor
- Boston Scientific Corporation
Coronary Stenosis
EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study
The study will enroll approximately 316 subjects with a wide spectrum of PCI indications (stable angina as well as ACS), who are considered to be at high risk of bleeding.
- Trial name
- NCT03877848
- Testing
- Percutaneous Coronary Intervention (PCI)
- Where
- Israel
- Volunteers
- 319 people
- Sponsor
- Medinol Ltd.
Coronary Arteriosclerosis, Acute Coronary Syndrome
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety
The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.
- Trial name
- GRAVITAS (NCT00645918)
- Testing
- clopidogrel
- Where
- 82 sites in United States, Canada
- Volunteers
- 2,800 people
- Sponsor
- Accumetrics, Inc.
Coronary Disease
Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis
The purpose of the study is to evaluate the effectively of coating of coronary stents with two different doses of rapamycin for the prevention of coronary vessel re-blockage
- Trial name
- NCT00152308
- Testing
- 2% rapamycin-eluting YUKONdes PEARL-stent, 1% rapamycin-eluting YUKONdes PEARL-stent
- Where
- 10 sites in Austria, Germany and 1 more
- Volunteers
- 333 people
- Sponsor
- Translumina GmbH
Coronary Artery Disease, Acute Coronary Syndrome
Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide™ Stent Versus Taxus™
Patients presenting with ACS (Acute Coronary Syndrome) in the emergency department will be screened for clinical eligibility and asked to sign informed consent to the study. A total of 40 patients will be randomized.
- Trial name
- OISTER (NCT00914420)
- Testing
- Intrepide Trapidil eluting stent, Taxus drug eluting stent
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Clearstream Technologies Ltd.
Coronary Stenosis
Excel Drug-Eluting Stent Pilot Clinical Registry
The Trial aims to evaluate long-term efficiency of Excel stent in the inhibition of restenosis as well as the safety after the cessation of the 6-month anti-platelet drug treatment.
- Trial name
- NCT00385905
- Testing
- Excel Drug-eluting stent
- Where
- China
- Volunteers
- 100 people
- Sponsor
- JW Medical Systems Ltd
Coronary Artery Disease
EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events
EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and…
- Trial name
- EDUCATE (NCT01069003)
- Testing
- Thienopyridine Therapy, Surveillance Arm
- Where
- United States
- Volunteers
- 2,272 people
- Sponsor
- Medtronic Vascular
In-Stent Restenosis or De Novo Coronary Artery Lesions
Coronary Artery Drug-Coated Balloon Dilatation Catheter Clinical Trial Protocol
This clinical trial adopts a retrospective, multicenter design with data registered and collected via an Electronic Data Capture (EDC) system.
- Trial name
- NCT07415902
- Testing
- Coronary Artery Drug-Coated Balloon Dilatation Catheter
- Where
- China
- Volunteers
- 252 people
- Sponsor
- DK Medical Technology (Suzhou) Co., Ltd.
Coronary Disease, Coronary Artery Disease
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ZoMaxx™ I (NCT00148356)
- Testing
- ZoMaxx™ Drug-Eluting Coronary Stent System, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
- Where
- 29 sites in Australia, Belgium and 8 more
- Volunteers
- 401 people
- Sponsor
- Abbott Medical Devices